Advertisement

 

 

Managing Fibromyalgia and Comorbid Depression

Managing Fibromyalgia and Comorbid Depression
Author Information (click to view)

Lesley M. Arnold, MD

Professor of Psychiatry
Director, Women’s Health Research Program
University of Cincinnati College of Medicine

Lesley M. Arnold, MD, has indicated to Physician’s Weekly that she has worked as a consultant in the past for Pfizer, Eli Lilly, Takeda, AstraZeneca, Forest Laboratories, Theravance, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Purdue Pharma

+


Lesley M. Arnold, MD (click to view)

Lesley M. Arnold, MD

Professor of Psychiatry
Director, Women’s Health Research Program
University of Cincinnati College of Medicine

Lesley M. Arnold, MD, has indicated to Physician’s Weekly that she has worked as a consultant in the past for Pfizer, Eli Lilly, Takeda, AstraZeneca, Forest Laboratories, Theravance, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Purdue Pharma

Advertisement

About 50% to 70% of fibromyalgia patients have a lifetime history of depression, many of whom take antidepressants to treat their depression. A common clinical question has been how to manage fibromyalgia pain in patients with comorbid depression who are stable on antidepressants. At the 2013 annual meeting of the American College of Rheumatology (ACR), my colleagues and I presented a study that addressed whether pregabalin—an FDA-approved agent for treating fibromyalgia—can help manage pain in patients concurrently taking antidepressants for depression.

New Data

Our study included 197 adults who met the ACR 1990 criteria for fibromyalgia. Participants had a documented diagnosis of depression, were on a stable dose of an antidepressant, and remained on these drugs throughout the 14-week study. Patients were then started on 150 mg/day of pregabalin, dosed twice daily; this was then optimized to 300 to 450 mg/day, dosed twice daily. The trial used a crossover, double-blind, placebo-controlled design. There were two 6-week periods; patients received pregabalin or placebo, with a 2-week break in between these periods.

Fibromyalgia-Depression-Callout

The average pain severity for patients at the onset of the study was 6.7 out of 10.0 (moderate to severe). Patients on pregabalin had a significant reduction in pain severity when compared with those on placebo. Pain improvement was noted by the first week of treatment and was maintained throughout the study. On average, patients on pregabalin experienced about a 28% reduction in pain severity.

The safety profile of pregabalin was consistent with previous fibromyalgia trials and the drug’s current product labeling. Treatment-emergent adverse events were reported by 77.3% of patients on pregabalin and 59.9% for the placebo group. There were four serious adverse events that were not considered related to the treatment; three of which occurred with pregabalin and one with placebo. Our analysis also demonstrated that 6.1% of participants discontinued pregabalin, and 3.4% discontinued placebo due to adverse events.

Important Implications

The results of our analysis indicate that fibromyalgia patients with comorbid depression who are on a stable dose of an antidepressant can benefit significantly with pregabalin. This treatment correlated with significantly lower pain severity when compared with placebo. With pain reduction occurring early and being maintained throughout the study, this represents an important potential strategy for clinicians to consider when managing fibromyalgia and comorbid depression.

Readings & Resources (click to view)

Arnold LM, Sarzi-Puttini P, Arsenault P, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and co-morbid depression receiving concurrent antidepressant therapy: a randomized, 2-way, crossover, double-blind, placebo-controlled study. Abstract #L6. Presented at 2013 American College of Rheumatology annual meeting. October 29, 2013. Abstract available at: https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/39039.

Arnold LM, Arsenault P, Huffman C, et al. Once daily controlled-release pregabalin in fibromyalgia patients: a phase 3 double-blind, randomized withdrawal, placebo-controlled study. Abstract #2850. Presented at 2013 American College of Rheumatology annual meeting. October 30, 2013. Abstract available at: https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/35543.

Uçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:CD010782.

Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily vs nightly dosing of pregabalin for fibromyalgia: a double blind, randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2013 Aug 27 [Epub ahead of print].

Martinotti G, Lupi M, Sarchione F, et al. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19:6367-6374.

Bellato E, Marini E, Castoldi F, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. 2012;2012:426130.

Wells AF, Arnold LM, Curtis CE, et al. Integrating health information technology and electronic health records into the management of fibromyalgia. Postgrad Med. 2013;125:70-77.

Submit a Comment

Your email address will not be published. Required fields are marked *

12 − eight =

[ HIDE/SHOW ]